Aldevron vs ReciBioPharm: CDMO Comparison

How does Aldevron compare to ReciBioPharm?

As of May 2026, Aldevron: 1 FDA inspection (including 1 NAI, 0 VAI and 0 OAI). Signal Score 80.3. ReciBioPharm: no FDA inspections on file, 3 EMA/MHRA GMP certificates. Signal Score 82.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.

Side-by-side comparison of Aldevron and ReciBioPharm on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Fargo, ND
Signal Score
80/100
Quality (FDA + GMP)
100/100
FDA inspections
1
— NAI / VAI / OAI
1 / 0 / 0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
0
Clinical programs (matched)
0
Capacity
—
Modalities
Plasmid, mRNA
Keele, UK · Sodertalje, SE
Signal Score
83/100
Quality (FDA + GMP)
100/100
FDA inspections
0
FDA warning letters
0
EMA GMP certificates (active)
0
MHRA GMP certificates (compliant)
3
Clinical programs (matched)
0
Capacity
—
Modalities
AAV, Lentiviral, Plasmid, mRNA

Key differences

  • Aldevron has FDA inspections on record (1); ReciBioPharm does not yet appear in the FDA inspection database.
  • Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
  • ReciBioPharm maintains 3 MHRA / UK GMP certificates; Aldevron does not.

Across the cross-modality scorecard, ReciBioPharm carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.

Frequently asked: Aldevron vs ReciBioPharm

How does Aldevron compare to ReciBioPharm?

On CDMO Signal's composite Signal Score, Aldevron is 80/100 and ReciBioPharm is 83/100; Aldevron has 1 FDA inspection on record vs 0 for ReciBioPharm; European coverage is 0 active EMA+MHRA certificates for Aldevron vs 3 for ReciBioPharm. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.

Which has the stronger FDA inspection record, Aldevron or ReciBioPharm?

Both Aldevron and ReciBioPharm maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Aldevron has 1 FDA inspection on record; ReciBioPharm has 0.

How do Aldevron and ReciBioPharm compare on European GMP coverage?

Aldevron holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. ReciBioPharm holds 0 active EMA GMP certificates and 3 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.

What does the Signal Score gap mean in practice?

Aldevron carries a Signal Score of 80/100 and ReciBioPharm carries 83/100 — essentially tied for ReciBioPharm. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.

Evaluating Aldevron and ReciBioPharm for a program?

Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.

Find & compare CDMOs →
Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.